Form 4 holding
Chief Scientific Officer
Zentalis Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 512,856
- Estimated value
- $877,753
- Report date
- 03 Feb 2025
- Price
- $1.71
- Ownership
- Direct
Mark Lackner - Chief Scientific Officer at Zentalis Pharmaceuticals, Inc.
Insider Transactions and Holdings
- Entity type
- Individual
- Role
- Chief Scientific Officer
- Issuer symbol
- ZNTL on Nasdaq
- Source filings
- Open source filing history
There are no Buy or Sell transactions made by Mark Lackner since 29 May 2025
Holdings reported by Mark Lackner for Zentalis Pharmaceuticals, Inc.
Form 4 holding
Chief Scientific Officer
Zentalis Pharmaceuticals, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 124,714
- Estimated value
- Report date
- 03 Feb 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transactions reported by Mark Lackner for Zentalis Pharmaceuticals, Inc.
| Sym | Class | Transaction | % | Reported value | Reported price | Shares | Shares after | Date | Ownership |
|---|
An asterisk next to the price means the reported price is likely invalid.